M. G. Lebwohl, “Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study”, J of Skin, vol. 4, no. 5, p. s38, Sep. 2020.